METHODS: We examined 224 patients who received adjuvant CAPOX therapy for CRC between July 2010 and December 2021 at our hospital. Patients were divided into \"Statin\" and \"Non-statin\" groups based on statin use. Details on and the adverse events of adjuvant CAPOX therapy were examined in association with statin use.
RESULTS: Thirty-one patients (14%) were treated with statins. There were no intergroup differences in the relative dose intensity or number of CAPOX cycles between the Statin and Non-statin groups. In total, 94% of patients in the Statin group and 95% of those in the Non-statin group developed OIPN (p=0.67). The severity of OIPN was similar between the two groups (p=0.89). The frequency of treatment delays in CAPOX did not significantly differ between the Statin and Non-statin groups (16% vs. 11%, p=0.45).
CONCLUSIONS: The efficacy of statins to attenuate OIPN during adjuvant CAPOX therapy was not apparent in the current study. Further studies are needed to confirm the present results.
方法:我们检查了在2010年7月至2021年12月期间在我院接受CAPOX辅助治疗CRC的224例患者。根据他汀类药物的使用将患者分为“他汀类药物”和“非他汀类药物”组。研究了CAPOX辅助治疗的细节和不良事件与他汀类药物使用的相关性。
结果:31例患者(14%)接受他汀类药物治疗。他汀组和非他汀组之间的相对剂量强度或CAPOX周期数没有组间差异。总的来说,他汀类药物组中94%的患者和非他汀类药物组中95%的患者发生OIPN(p=0.67)。两组之间OIPN的严重程度相似(p=0.89)。他汀组和非他汀组之间CAPOX的治疗延迟频率没有显着差异(16%vs.11%,p=0.45)。
结论:在目前的研究中,他汀类药物在辅助CAPOX治疗期间减弱OIPN的功效并不明显。需要进一步的研究来证实目前的结果。